OrthoPediatrics Corp · Q4 2023 earnings

Briefing

OrthoPediatrics reported strong Q4 2023 results with revenue growth driven by trauma and deformity, scoliosis, and OPSB.

OrthoPediatrics Corp. announced its Q4 and full year 2023 financial results, with Q4 revenue increasing by 21% to $37.6 million compared to the same period last year. The company's growth was primarily driven by Global Trauma and Deformity, Domestic Scoliosis, and OPSB. The net loss for the quarter was $6.7 million, an improvement compared to the $7.8 million loss in the same period last year. Adjusted EBITDA for the fourth quarter of 2023 was $1.3 million as compared to a loss of $2.2 million for the fourth quarter of 2022.

• Helped nearly 20,000 children in Q4 2023.
• Q4 2023 revenue increased 21% year-over-year to $37.6 million.
• U.S. revenue increased 24% and international revenue increased 13% in Q4 2023.
• Gross profit for the fourth quarter of 2023 was $26.7 million, a $5.5 million increase compared to $21.2 million for the same period last year.

Headline financials

Revenue & EPS history

The Company expects its revenue to be in the range of $197.0 million to $200.0 million, representing growth of 32% to 34% over 2023 revenue. The Company also expects its annual set deployment to be less than $20.0 million and expects to generate $8.0 million to $9.0 million of adjusted EBITDA for full year 2024.